Recommendations for Treating Hypertension
What Are the Right Goals and Purposes?

Eric D. Peterson, MD, MPH; J. Michael Gaziano, MD; Philip Greenland, MD

Hypertension is the most common cardiovascular risk factor in the United States, affecting approximately two-thirds of adults aged 60 years or older. Observational studies have demonstrated a linear relationship between blood pressure (BP) and risk of cardiovascular events. Randomized controlled trials (RCTs) have found that lowering BP by as little as 10 mm Hg in patients with hypertension can reduce a person’s lifetime risk for cardiovascular and stroke death by 25% to 40%. Yet for such a common and treatable condition, the ideal treatment goal remains uncertain—both overall and as a function of a patient’s age. Compared with younger patients, older patients with hypertension are at increased risk for cardiovascular and stroke events yet are more vulnerable to complications related to pharmacological treatment of hypertension.

The last Joint National Committee (JNC 7) Guideline, sponsored by the National Heart, Lung, and Blood Institute (NHLBI), was released more than a decade ago. The updated recommendations for management of high blood pressure from the NHLBI. The panel's report is now published in JAMA as a stand-alone document, and it remains unclear as to whether, or when, or by whom another consensus national hypertension guideline will again be formulated.

Where does this leave practitioners, patients, and policymakers? The major difference between the JNC 7 report and the current panel recommendations centers on whether target BP treatment goals should be more conservative (ie, set higher) in older vs younger populations. Specifically, JNC 7 concluded that all adult patients with hypertension (regardless of their age) should have their BP reduced to a systolic BP (SBP) of lower than 140 mm Hg, with even tighter control in patients with diabetes or renal disease (SBP <130 mm Hg). In contrast, the current recommendation raises target SBP goals to 150 mm Hg or lower in those aged 60 years or older, while eliminating the tighter control recommendations in patients with diabetes and renal disease.

How the panel selected these treatment goals depended in part on how existing trial evidence (or lack thereof) was interpreted. Prior guidelines were generally based on the totality of evidence, including observational studies, RCTs, and meta-analyses, as well as expert opinion. Noting that the risks for cardiovascular events in untreated adults increased rapidly as SBP was elevated beyond 140 mm Hg, experts defined hypertension and its treatment targets at this level. Nevertheless, direct RCT evidence to support this threshold is limited. The original hypertension RCTs were selective and generally excluded elderly patients. Later trials that focused specifically on older populations found that treating isolated SBP was beneficial, yet these trials had treatment intervention targets of SBP lower than 160 mm Hg. More recently, 2 Japanese RCTs directly compared a more intensive treatment strategy (lowering SBP <140 mm Hg) vs a more conservative one (~150 mm Hg) among older patients (~65 years). Neither trial found a significant difference in the primary outcome, yet both trials had relatively short follow-up and limited overall power to exclude a clinically meaningful difference in outcomes. The evidence gap for patients younger than 60 years is even more profound because no RCTs have specifically addressed ideal SBP targets in this age group.

These limitations in the available RCT evidence pool created challenges for determining consensus recommendations. Does the absence of evidence lead to the conclusion of evidence of absence? In this case, panel members came to different conclusions. In older populations, the majority of the panel interpreted the lack of definitive benefit from RCTs as grounds to raise the SBP treatment goal recommendation to 150 mm Hg; however, for patients younger than 60 years, the paucity of any trial evidence provided no reason for the panel to change the existing treatment goal of SBP at 140 mm Hg.

How the panel’s conclusions are viewed may partially be influenced by the recommendations’ ultimate purpose. The original term for practice “guidelines” was borrowed from a mountain-climbing technique in which experienced guides marked the best and safest paths for hikers to take by placing ropes along the way. In medicine, clinicians initially formed guidelines to suggest a safe direction when managing difficult clinical situations. If this original purpose had remained intact, then the debate around a specific SBP threshold would most likely not be so intense. Clinicians would still be free to consider more aggressive treatment goals for a healthy asymptomatic 60-year-old patient, while electing a more conservative treatment goal for a 75-year-old patient with a history of falls. Yet over time, as guidelines have become more formalized, deviations from guideline recommendations have become less tolerated. Furthermore, guideline recommenda-
Hypertension recommendations have now been distilled into “performance measures,” which use rigid criteria to assess physicians’ quality of care. Rather than merely suggesting a course of action, performance measures define what a clinician should and must do to avoid a quality concern. As a result, performance metrics are increasingly linked to public reporting and pay-for-performance programs, providing powerful incentives for measuring performance. It also must be recognized that the philosophy used to create both past and present hypertension recommendations differs from that used in the recent revisions of the cholesterol guidelines. The authors of the new cholesterol treatment guidelines emphasized assessing an individual’s aggregate cardiovascular risk and then treating those at greatest overall risk with more aggressive therapy. Because older individuals have higher cardiovascular risk profiles, they more frequently receive a recommendation for intervention. Rather than considering a patient’s total risk profile, the current panel’s hypertension recommendations focus on a single risk factor (ie, BP) and recommend less (as opposed to more) aggressive treatment of BP in older individuals. These differences may be rationalized based on the adverse effect profiles of the 2 interventions, yet such divergent philosophies may cause confusion among clinicians and patients alike.

While it is likely that there will be considerable controversy in hypertension treatment for the foreseeable future, several critical next steps are needed. First, larger RCTs need to compare different BP thresholds in diverse patient populations. Ideally, these investigations would be conducted using the evolving strategies of practical clinical trial designs to improve their efficiency and real-world generalizability. Second, there is an important need to create a national consensus group to draft an updated comprehensive practice guideline that would harmonize the hypertension guideline with other cardiovascular risk guidelines and recommendations, thereby resulting in a more coherent overall cardiovascular prevention strategy. This group should include representatives from multiple specialties and primary care disciplines, should follow the Institute of Medicine recommendations for guideline development, and should cover the full range of cardiovascular care topics, to develop an integrated approach for prevention, detection, and evaluation, along with treatment goals. Individual recommendations from discrete guidelines—such as for hypertension, cholesterol, and obesity—do not reflect the integrated care needed for many patients seen in practice. Third, the process of translating practice guidelines into performance measures needs to be more deliberate. For example, performance measures derived from guidelines need to be cognizant of the potential unintended consequences if treatment goals are set too strict or adherence to these is too rigid. Finally, once the right targets for BP thresholds are determined, patients and physicians need to work together to consistently achieve these new goals.

**ARTICLE INFORMATION**

**Author Affiliations:** Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (Peterson); VA Boston Healthcare System and Division of Aging, Brigham and Women’s Hospital, Boston, Massachusetts (Gaziano); Northwestern University, Chicago, Illinois (Greenland); Associate Editor, JAMA (Peterson, Gaziano); Senior Editor, JAMA (Greenland).

**Published Online:** December 18, 2013. doi:10.1001/jama.2013.284430.

**Corresponding Author:** Eric D. Peterson, MD, MPH; Duke Clinical Research Institute, 2400 Pratt St, Room 0311, Terrace Level, Durham, NC 27705 (eric.peterson@duke.edu).

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

**REFERENCES**


3. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection,


